Comment on FDA approves first in class targeted therapy for metastatic pancreatic cancerparentComments−norbertsboat16dThe FDA article lists 5 reasons the pilot of the pilot is only for the non controversial one that is not even listed in a way that maximizes its risk/benefit requirements.
Comments
The FDA article lists 5 reasons the pilot of the pilot is only for the non controversial one that is not even listed in a way that maximizes its risk/benefit requirements.